Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Cancer Diagnostics Market is Expected to Reach $232.7 Billion by 2025: Grand View Research, Inc.

Grand View Research,Inc.
Posted on: 01 Dec 16

PR Newswire

SAN FRANCISCO, December 1, 2016

SAN FRANCISCO, December 1, 2016 /PRNewswire/ --

The global cancer diagnostics market is expected to reach USD 232.7 billion by 2025, according to a new report by Grand View Research, Inc. Continual introduction of innovative products coupled with increasing need for early diagnosis of the disease is the prime factor driving the market growth.

     (Logo: http://photos.prnewswire.com/prnh/20150105/723757 )

In addition, rapid growth of the sector is attributed to the penetration of technologically advanced laboratory systems that have improved oncological screening in yielding accurate outcomes. Rising incidence of cancer is triggering the demand for these screening tests and imaging modalities that are used for monitoring disease progression.

Collaborative and independent initiatives led by governments and companies are striving to raise cognizance about the benefits of early diagnosis of the disease. In addition, cancer research organizations along with public and private entities are investing heavily on research projects to launch advanced diagnostic tools in the market, which are capable of diagnosing the disease way before the symptoms appear.

Furthermore, giant players are collaborating with governments and other agencies to enhance patient accessibility of their products. For instance, Illumina, Inc. launched a new venture named GRAIL with investors, Jeff Bezos and Bill Gates, with an investment of more than $100 million. GRAIL is mainly focused on blood-based oncological screening for timely diagnosis of the most common tumor types through simple laboratory tests.

Browse full research report with TOC on " Cancer Diagnostics Market Analysis By Type (Laboratory Tests, Genetic Tests, Imaging, Endoscopy, Biopsy), By Application (Breast, Lung, Liver, Cervical, Colorectal, Skin, Blood, Kidney, Prostate, Ovarian And Pancreatic Cancer) And Segment Forecasts, 2014 - 2025 " at: http://www.grandviewresearch.com/industry-analysis/cancer-diagnostics-market

Further Key Findings from the Study Suggest:

  • Rapid adoption of technology and escalating need for early diagnosis is augmenting the growth of the imaging systems space.
  • The breast cancer segment, among other application segments, accounted for the largest share due to the high incidence rate of breast cancer triggering the need for its early diagnosis.
  • In 2015, North America dominated the global space with the largest revenue share of more than 40%.
  • Focused research efforts in oncology for the development of early tumor detection tools coupled with grants from government healthcare agencies are contributing to a strong medical ecosystem to fight cancer in this region.
  • Asia Pacific is expected to emerge as the fastest growing region during the forecast period.
  • The growing patient pool in India, China, and Japan; due to the support in diagnostic process at comparatively lower prices; and a favorable regulatory framework are some of the factors boosting the market growth in this region.
  • Major players competing in this market include GE Healthcare; Abbott; Hoffmann-La Roche Ltd and Siemens Healthcare GmbH.
  • Other prominent players operating in the market include but are not limited to Becton Dickinson & Company; Illumina, Inc.; Koninklijke Philips N.V.; and Hologic, Inc.

Browse related reports by Grand View Research:

Grand View Research has segmented the cancer diagnostics market by type, application, and region:

  • Cancer Diagnostics Type Outlook (Revenue, USD Billion; 2014 - 2025)
    • Laboratory Tests
    • Genetic Tests
    • Imaging
    • Endoscopy
    • Biopsy
    • Others (barium enema)
  • Cancer Diagnostics Application Outlook (Revenue, USD Billion; 2014 - 2025)
    • Breast Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Lung Cancer
    • Prostate Cancer
    • Skin Cancer
    • Blood Cancer
    • Kidney Cancer
    • Liver Cancer
    • Pancreatic Cancer
    • Ovarian Cancer
    • Others
  • Cancer Diagnostics Regional Outlook (Revenue, USD Billion; 2014 - 2025)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • China
      • Japan
      • India
    • Latin America
      • Mexico
      • Brazil
    • MEA
      • South Africa

Access research insight: http://www.grandviewresearch.com/research-insights/cancer-diagnostics-market-insights-size

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Read Our Blogs - http://www.grandviewresearch.com/blogs/healthcare


Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com

SOURCE Grand View Research, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 01/12/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.